An Open Label, Safety/Efficacy Study to Assess the Potential for Adrenal Suppression Following Multiple Dosing With Desoximetasone 0.25% Topical Spray in Patients With Moderate to Severe Plaque Psoriasis.

Trial Profile

An Open Label, Safety/Efficacy Study to Assess the Potential for Adrenal Suppression Following Multiple Dosing With Desoximetasone 0.25% Topical Spray in Patients With Moderate to Severe Plaque Psoriasis.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2014

At a glance

  • Drugs Desoximetasone (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Taro Pharmaceuticals USA
  • Most Recent Events

    • 05 Nov 2010 Planned end date changed from 1 Jul 2010 to 1 Jun 2010 as reported by ClinicalTrials.gov..
    • 05 Nov 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Feb 2010 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top